End-stage Liver Disease
Conditions
Interventions
Pure Laparoscopic full-size Liver Transplantation Group.:Pure laparoscopic full-size liver transplantation
Sponsors
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Donor Inclusion Criteria (meet the following 2 criteria): 1. Brain-dead organ donation (DBD) donors; 2. >=16 years; Receptor inclusion criteria (meet the following 5 criteria): 1. Age>=18 years and <=75 years; 2. Patients with end-stage liver disease who are on the liver transplant waiting list; 3. Agree to accept donor liver from brain-dead patients (DBD); 4. Large abdominal space, small size of diseased liver, and spontaneous portosystemic shunt; 5. The person or guardian agrees to participate in the clinical study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Donor Exclusion Criteria (meet any of the following): 1. Donor liver for split liver transplantation or reduced-volume liver transplantation; 2. HIV-positive patients donor liver; 3. Presence of moderate to severe hepatic trauma, active hepatic bleeding, liver abscess or even after reconstruction that affects effective perfusion Note the anatomical variation of the portal vein or hepatic artery of the donor liver. 4. Huge donor liver 5.4 Recipient exclusion criteria (meet any of the following): 1. Multi-organ transplantation or combined organ transplantation; 2. ABO incompatible liver transplantation 3. Patients with fulminant liver failure 4. Pregnant women; 5. Have a history of organ transplantation or bone marrow transplantation; 6. Ventilator-assisted ventilation is required before enrollment; 7. Intravenous vasoconstrictor drugs should be administered to maintain hemodynamic stability before enrollment; 8. Continuous renal replacement therapy is required before enrollment; 9. Subjects who are in other interventional clinical trials and have not met the study endpoints; 10. Other conditions that the investigator considers inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lGSAE; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Incision Complications.;Incidence of Post-reperfusion Syndrome;Patient satisfaction with the incision, quality of life;Incidence of Surgical Complications;Graft survival, recipient survival.;Incidence of Early Allograft Dysfunction; | — |
Countries
China
Contacts
Public ContactWu Wenrui
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Outcome results
None listed